Abstract
Biotechnology investments have been historically rewarding, but with the recent advances in and excitement about mapping the human genome, interest in this sector has been explosive. As the boundaries between life sciences and information sciences blur and the disciplines cross-fertilize, new business models are emerging for endeavours encompassing gene identification and therapeutic drug targeting. Yet competition is strong and drug development is costly. Picking the winners demands reliance on the fundamental principals of sound investing.
- © 2001 Pageant Media Ltd
Don’t have access? Click here to request a demo
Alternatively, Call a member of the team to discuss membership options
US and Overseas: +1 646-931-9045
UK: 0207 139 1600